Social network
Media - Staying connected to our latest news and events
Media - Staying connected to our latest news and events


Staying connected to our latest news and events

Tools content (print, share, increase/decrease text size):


Middle area:

Press releases 2013

Press releases are intended for journalists, analysts and investors.

Genzyme Receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) Application

December 30, 2013

Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program

December 19, 2013

Merial Receives EMA approval for Broadline™ for Broad Spectrum Parasite Treatment and Prevention in Cats

December 12, 2013

FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease

December 11, 2013

New Data Support Flexibility in Timing of Administration for Sanofi’s Lyxumia®

December 05, 2013

Sanofi Announces New Phase 3 Results for Investigational New Insulin U300

December 03, 2013

Sanofi and Regeneron’s Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence

November 25, 2013

Sanofi Pasteur commends GAVI Alliance for Supporting the Introduction of Inactivated Polio Vaccine in World’s Poorest Countries

November 22, 2013

Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial

November 22, 2013

Sanofi Discontinues Clinical Development of Investigational JAK2 Agent Fedratinib (SAR302503)

November 18, 2013

Sanofi successfully prices EUR 1 billion bond issue

November 07, 2013

Sanofi and the Institut Pasteur Reward Four International Scientists for their Innovative Research in Life Sciences

November 05, 2013

Q3 2013 Marks the End of the Patent Cliff Period

October 30, 2013

Sanofi Launches “Action 2013”, a Worldwide Employee Stock Purchase Plan

October 29, 2013

Sanofi Pasteur Announces Vaccine Discovery Collaboration with the Bill & Melinda Gates Foundation

October 29, 2013

Sanofi Celebrates 50th Anniversary of Elysée Treaty

October 21, 2013

Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction

October 16, 2013

Sanofi Hosts French President François Hollande at Facility in South Africa

October 15, 2013

FDA Approves Sanofi’s Nasacort® Allergy 24HR for Over-the-Counter Use

October 11, 2013

Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

October 03, 2013

Sanofi and Aviesan Renew their Agreement to Accelerate Research in France

September 27, 2013

Sanofi strengthens its presence in Algeria

September 26, 2013

Data Show Sanofi’s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled

September 24, 2013

U.S. FDA Approves Merial’s NexGard™ (afoxolaner) Chewables for Treatment and Prevention of Fleas and Ticks in Dogs

September 24, 2013

Sanofi’s CSR Achievements Recognized by Two Global Indices

September 19, 2013

European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)

September 17, 2013

Sanofi Re-Introduces Rolaids® in the United States

September 16, 2013

Sanofi Provides Update on Lixisenatide New Drug Application in U.S.

September 12, 2013

Menomune® Is the First Quadrivalent Meningococcal Vaccine Prequalified by the WHO

September 03, 2013

European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)

August 30, 2013

Sanofi successfully prices EUR 1 billion bond issue

August 29, 2013

Sanofi Pasteur’s Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older

August 26, 2013

Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium Difficile Vaccine

August 05, 2013

Online Availability of Sanofi Group’s Half-Year Financial Report for 2013

August 02, 2013

Q2 2013: Last Quarter with Significant Negative Impact from the Patent Cliff

August 01, 2013

FDA Advisory Committee Recommends Approval of Sanofi’s Nasacort® AQ Nasal Spray for Over-the-Counter Use

July 31, 2013

Sanofi Appoints Carsten Hellmann and David Meeker to the Executive Committee

July 31, 2013

Genzyme Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe

June 28, 2013

Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin

June 28, 2013

Sanofi Expands Collaboration with GDF SUEZ to Reduce its Global Energy Consumption

June 24, 2013

Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300

June 22, 2013

Curie-Cancer and Sanofi cooperate in research on ovarian cancer

June 19, 2013

Sanofi to present new clinical data, including results from the investigational new insulin U300, at the American Diabetes Association 73rd Scientific Sessions

June 18, 2013

New Four-Strain Influenza Vaccine from Sanofi Pasteur Now Licensed By FDA for Broad Age Range of Children and Adults

June 10, 2013

ORIGIN Results on Lantus® Cardiovascular Safety Integrated Into European Union Product Label

June 05, 2013

Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds

June 03, 2013

Sanofi appoints David Loew, Senior Vice President, Commercial Operations, Europe

May 23, 2013

Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine

May 21, 2013

Sanofi announces the next steps of its Research site in Toulouse, France

May 17, 2013

Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis

May 17, 2013

Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

May 15, 2013

Combined General Shareholder Meeting of May 3, 2013

May 03, 2013

Q1 2013 business EPS impacted by exclusivity losses in prior year. Growth platforms sales increased 8.6%

May 02, 2013

Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization

May 02, 2013

Sanofi and DNDi celebrate six years of collaboration in fighting malaria by distributing 200 million treatments of ASAQ

April 25, 2013

Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study

April 25, 2013

Sanofi Pasteur to Provide 1.7 Billion Doses of Oral Polio Vaccine from 2013 to 2017 for Polio Eradication

April 24, 2013

Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe

April 22, 2013

Sanofi reinforces its presence in Morocco

April 17, 2013

Sanofi strengthens its French-German partnership on the occasion the French-German Week for Science and Alumni

April 15, 2013

Sanofi and PATH announce the Launch of Large-scale Production of Semisynthetic Artemisinin against Malaria

April 11, 2013

Sanofi Pasteur’s New Quadrivalent Influenza Vaccine Accepted for Review for European Approval

April 11, 2013

Sanofi successfully prices USD 1.5 billion bond issue

April 04, 2013

Sanofi to Invest USD 75 million in a New Manufacturing Facility in Vietnam

March 29, 2013

Sanofi signs collaboration agreement with Schneider Electric to accelerate its energy efficiency program on its industrial sites

March 28, 2013

Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments

March 25, 2013

Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple Sclerosis

March 22, 2013

Effect of Genzyme’s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies

March 21, 2013

Genzyme’s Multiple Sclerosis Franchise Featured at AAN

March 13, 2013

Filing of the 2012 U.S. Form 20-F and French “Document de Référence" containing the Annual Financial Report

March 08, 2013

Composition of the Board of Directors of Sanofi

March 05, 2013

Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab

March 02, 2013

Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)

February 27, 2013

European Medicines Agency Recommends Approval of Hexyon/Hexacima 6-in-1 Pediatric Vaccine

February 22, 2013

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

February 19, 2013

Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease

February 15, 2013

The Sanofi Espoir Foundation and the Union for International Cancer Control are extending their My Child Matters partnership for another three years

February 14, 2013

Sanofi delivers solid 2012 results despite patent expirations

February 07, 2013

ZALTRAP® (aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer

February 05, 2013

Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe

February 04, 2013

Genzyme and Isis Announce FDA Approval of KYNAMRO™ (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia

January 29, 2013

Sanofi Announces Auvi-Q™, the First and Only Voice-Guided Epinephrine Auto-Injector, is Now Available in the U.S.

January 28, 2013

Genzyme’s LEMTRADA™ (alemtuzumab) Application for MS Accepted for Review by the FDA

January 28, 2013

Sanofi Provides an Update on its Research & Development Pipeline

January 08, 2013

Sanofi’s Chattem Acquires Over-the-Counter Antacid Rolaids®

January 07, 2013

Sanofi Appoints Dr. Gary J. Nabel as Chairman of the Strategic Development and Scientific Advisory Council

January 07, 2013

Right area:




Filter by date


© Sanofi 2004-2016 - All rights reserved - Update: March 12, 2015

  • Site complies with W3C WCAG 2.0 (new window, in english)